FDA Reviews Mifepristone Access Rules as Courts Pause Abortion Pill Litigation

The federal regulatory framework governing mifepristone, the drug used in a majority of abortions in the United States, entered a new phase Thursday when a federal district court froze litigation for six months and the FDA began an internal review of its 2023 decision to allow mail distribution and retail pharmacy dispensing of the abortion pill.

That 2023 decision materially expanded access to medication abortion by eliminating the requirement that mifepristone be dispensed in person by a physician, a restriction that governed the drug since its FDA approval more than 25 years ago. The shift opened retail pharmacy and telehealth channels that became a critical route for patients, particularly in states with restrictive abortion laws where certain exceptions or uneven enforcement left limited options.

The litigation freeze came in a case brought by Louisiana, which sued to challenge the 2023 dispensing expansion. The district court, recognizing the FDA as the appropriate scientific authority on drug safety questions, placed its proceedings on hold while the agency conducts its review. Louisiana has since filed an appeal with the Fifth Circuit, meaning the appellate court could act independent of the FDA's timeline and potentially upend the current dispensing regime before the internal review concludes.

HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary cited a report produced by a conservative organization as a basis for initiating the review, a rationale that reproductive rights advocates have characterized as politically motivated and methodologically unsound.

On Capitol Hill, Senator Josh Hawley introduced the Safeguarding Women from Chemical Abortion Act, legislation that would attempt to rescind the FDA's approval of mifepristone entirely. The bill confronts significant legal and political obstacles, but its introduction reflects how far some Republican lawmakers are willing to go beyond existing regulatory channels. Several other Republican senators also launched separate investigations seeking adverse event data from mifepristone manufacturers.

The district court's deference to FDA expertise reflects a well-established legal principle: courts generally defer to agencies on technically complex safety matters while retaining oversight authority. Whether that deference holds if the Fifth Circuit moves aggressively on Louisiana's appeal remains a central uncertainty.

For clinicians, the review generates immediate uncertainty around standard-of-care protocols and telehealth abortion practices. Mail dispensing and remote prescription channels became especially significant in states that ban abortion but permit narrow exceptions, and any reversal of the 2023 rules would sharply curtail those options, with consequences falling disproportionately on patients in the most restrictive states.

The FDA's internal review period and any Fifth Circuit ruling are both expected to resolve before the end of 2026. How those two tracks develop will determine whether the expanded dispensing rules that have governed mifepristone access for the past three years remain intact or are substantially narrowed.